Quanta Raises £27 Million to Prepare its Advanced Haemodialysis System SC+ for Launch.

Alcester, Warwickshire, UK, 3 November 2014: Quanta Fluid Solutions Ltd (“Quanta”) a pioneering developer of advanced haemodialysis systems, today announced that it has closed a fundraising of approximately £27 million. The funding round was led by ALIAD, the venture capital investment vehicle of Air Liquide SA (Paris: AI), and included participation by new investor Seventure Partners, as well as existing investors Wellington Partners, Seroba Kernel, b-to-v Partners and IMI plc (LSE: IMI).

Funds will be used to support the clinical introduction and commercial launch of SC+, Quanta’s advanced haemodialysis system. SC+ is the only portable, compact haemodialysis system in development providing the clinical efficacy and high flow rates comparable to in-centre machines. SC+ is designed to provide a significant change in the way dialysis patients are treated, with its unique cartridge-based design that allows greater ease-of-use and treatment flexibility, whether in-centre or in the home.

John E. Milad, Chief Executive Officer of Quanta, said “This funding will support our activities as we progress SC+ towards clinical introduction and subsequent commercial launch. We are delighted to welcome our new investors ALIAD and Seventure Partners, who share our vision of improving renal care for patients and healthcare professionals.”


About Quanta
Quanta is developing advanced haemodialysis systems for use in the clinic and the home. The Company’s cartridge-based solution SC+ is the only portable, compact haemodialysis system with the clinical efficacy and high flow rates of traditional machines. SC+ is designed to offer ease-of-use and flexibility, facilitating self-care and supporting dialysis patients across the entire continuum of care.

Quanta is privately owned and based in Alcester, UK. The Company was founded in 2008 as a spin out from the FTSE 100 engineering company IMI plc. Funding has been provided by a group of leading venture capital investors specialised in healthcare: initially NBGI Ventures, Wellington Partners, Seroba Kernel and b-to-v Partners, and more recently ALIAD and Seventure Partners.

Quanta is dedicated to creating a paradigm shift in renal care and to improving the lives of dialysis patients.

For more information please visit: www.quantafs.com

About End Stage Renal Disease and Haemodialysis

Lifestyle choices, modern diet and increased life expectancy are all negatively impacting renal health across the globe, and End Stage Renal Disease (ESRD) affects millions of patients worldwide. Haemodialysis is a life-saving treatment delivered to an estimated 2 million people with ESRD globally—with this figure expected to double in the next decade.

At present, haemodialysis is primarily provided by specialist clinics and centres. However this means that the patient is not in control of when they can dialyse. It is clinically demonstrated that more frequent dialysis and/or longer treatment sessions improve outcomes and quality of life for patients, and a number of studies have shown that 30-40% of patients would be capable of performing self-dialysis.

Issues of patient benefit, cost and clinic capacity are driving the growth of home and self-care modalities of haemodialysis, but a major factor limiting the growth of self-care and home haemodialysis is the lack of convenient, portable and easy-to-use dialysis systems. SC+ addresses these issues and puts the patient at the centre, allowing them to take greater control of their treatment.

For further information, please contact:

Vicky La Touche-Price, Seroba Kernel Life Science.
Tel: +35316334028.

< back to home page